Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) is -55.57% lower on its value in year-to-date trading and has touched a low of $1.58 and a high of $19.95 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AMLX stock was last observed hovering at around $6.22 in the last trading session, with the day’s gains setting it 0.32%.
Currently trading at $6.54, the stock is 31.87% and 78.16% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.73 million and changing 5.14% at the moment leaves the stock 39.42% off its SMA200. AMLX registered -64.04% loss for a year compared to 6-month gain of 246.03%. The firm has a 50-day simple moving average (SMA 50) of $3.5818 and a 200-day simple moving average (SMA200) of $4.73015.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 92.92% loss in the last 1 month and extending the period to 3 months gives it a 244.21%, and is 21.11% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.41% over the week and 11.78% over the month.
Amylyx Pharmaceuticals Inc (AMLX) has around 384 employees, a market worth around $445.26M and $298.76M in sales. Profit margin for the company is -55.52%. Distance from 52-week low is 315.24% and -67.22% from its 52-week high. The company has generated returns on investments over the last 12 months (-63.29%).
The EPS is expected to shrink by -623.81% this year
168.0 institutions hold shares in Amylyx Pharmaceuticals Inc (AMLX), with institutional investors hold 109.91% of the company’s shares. The shares outstanding are 67.71M, and float is at 41.21M with Short Float at 2.45%. Institutions hold 94.14% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 4.22 million shares valued at $8.03 million. The investor’s holdings represent 6.2251 of the AMLX Shares outstanding. As of 2024-06-30, the second largest holder is AQR CAPITAL MANAGEMENT LLC with 3.34 million shares valued at $6.35 million to account for 4.9237 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 2.67 million shares representing 3.9345 and valued at over $5.07 million, while GOLDMAN SACHS GROUP INC holds 3.8471 of the shares totaling 2.61 million with a market value of $4.96 million.
Amylyx Pharmaceuticals Inc (AMLX) Insider Activity
The most recent transaction is an insider sale by Klee Justin B., the company’s Co-Chief Executive Officer. SEC filings show that Klee Justin B. sold 18,589 shares of the company’s common stock on Sep 30 ’24 at a price of $3.20 per share for a total of $59429.0. Following the sale, the insider now owns 3.12 million shares.
Amylyx Pharmaceuticals Inc disclosed in a document filed with the SEC on Sep 30 ’24 that Cohen Joshua B (Co-Chief Executive Officer) sold a total of 18,589 shares of the company’s common stock. The trade occurred on Sep 30 ’24 and was made at $3.20 per share for $59414.0. Following the transaction, the insider now directly holds 3.22 million shares of the AMLX stock.
Still, SEC filings show that on Sep 30 ’24, Bedrosian Camille L (Chief Medical Officer) disposed off 11,442 shares at an average price of $3.20 for $36559.0. The insider now directly holds 143,801 shares of Amylyx Pharmaceuticals Inc (AMLX).
